OncoMatch/Clinical Trials/NCT05438043
A Study of Daratumumab
Is NCT05438043 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for multiple myeloma.
Treatment: Daratumumab · Carfilzomib · Dexamethasone · Lenalidomide · Pomalidomide — The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have reached clinical cutoff for final analysis. Certain long-term safety data will continue to be collected from study participants.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Endocrine / hormonal
Other
Cancer type
Multiple Myeloma
Prior therapy
Must have received: daratumumab (daratumumab) — parent Janssen R&D daratumumab study
Participants must be actively receiving daratumumab (either as monotherapy or in combination with other study treatment) in certain Janssen research and development (R&D) studies or receiving other study treatment in a Janssen R&D daratumumab study for participants with multiple myeloma or smoldering multiple myeloma which has reached clinical cutoff for final analysis continue to benefit from study treatment, not have experienced disease progression or unmanageable toxicity while receiving daratumumab, not have met the withdrawal criteria set forth in the parent study, and have had the last dose of study treatment within the previous 3 months
Cannot have received: disallowed therapies or treatment for the disease under study
Has taken any disallowed therapies or treatment for the disease under study between the completion of the parent study and the planned first dose of study treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Miami Sylvester Cancer Center · Miami, Florida
- Emory University · Atlanta, Georgia
- University of Michigan Comprehensive Cancer Center · Ann Arbor, Michigan
- Barnes-jewish Hospital · St Louis, Missouri
- Icahn School of Medicine at Mount Sinai - The Derald H. Ruttenberg · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05438043 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior disallowed therapies or treatment for the disease under study disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages